Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Misses Expectations By $1.25 EPS

Key Points

• Whitehawk Therapeutics reported a quarterly EPS of ($0.76), missing consensus estimates by $1.25.
• The company's negative return on equity was recorded at 85.57%, paired with a net margin of 99.42%.
• Despite the earnings miss, WHWK stock saw a 1.7% increase during midday trading, reaching $1.75.

Whitehawk Therapeutics (NASDAQ:WHWK - ) announced its quarterly earnings results on Thursday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($1.25), Zacks reports. Whitehawk Therapeutics had a negative return on equity of 85.57% and a net margin of 99.42%.

Whitehawk Therapeutics Trading Up 1.7%

WHWK stock traded up $0.03 during midday trading on Friday, hitting $1.75. The company's stock had a trading volume of 65,828 shares, compared to its average volume of 88,549. Whitehawk Therapeutics has a 1 year low of $1.32 and a 1 year high of $3.81. The stock has a market cap of $82.44 million, a P/E ratio of -29.17 and a beta of 0.55.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.